Given the heavy regulation of the healthcare industry, transactions for healthcare companies demand a broader skill set than that offered by traditional corporate attorneys alone. Instead, healthcare transactions today require law firms with a strong combination of both healthcare regulatory expertise and corporate transactional experience.
King & Spalding offers corporate transactional attorneys specializing in health industry transactions who have deep experience in the unique business, regulatory, reimbursement and risk allocation factors that shape healthcare industry transactions. Our practice is national in scope and involves all substantive aspects of healthcare transactions, including multi-state regulatory approvals, legal risk assessments, tax structuring, antitrust analysis, as well as public company and going private issues.
Purchasers frequently engage our health industry lawyers for specialized due diligence examinations of target company compliance history relating to anti-kickback, Stark, FDA, reimbursement and other laws. Our deep experience in this area can speed the process of identifying and assessing the regulatory risks associated with proposed transactions.
We believe that this combination of traditional corporate and healthcare transactional experience provides a depth of knowledge and base of experience that allows us to deliver a unique, high-quality service, focused on resolving the issues of most importance to our clients.
Recognitions:
- Recognized as a leading law firm in the area of Corporate/M & A by Chambers USA: America’s Leading Lawyers for Business 2007
- A Senior transactional attorney is one of 12 Outstanding Healthcare Transaction Lawyers according to Nightingale’s Healthcare News in 2006
Representative Public Company Transactions:
- AmeriChoice Corporation sale to UnitedHealthGroup Inc. ($560 million)
- Caremark Rx, Inc. merger with CVS ($26 billion)
- Caremark Rx, Inc. acquisition of Advance PCS ($5.6 billion)
- Horizon Medical Products, Inc. merger with RITA Medical Systems, Inc. ($104 million)
- Per-Se Technologies, Inc. sale to McKesson Corp. ($1.8 billion)
- Per-Se Technologies, Inc. acquisition of NDC Health Corporation ($1 billion)
- Serologicals Corporation sale to Millipore Corporation ($1.4 billion)
